logo Bright Minds.png
Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference
December 06, 2021 06:50 ET | Bright Minds Biosciences
VANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Logo.jpg
Company to Present at Sequire Clean Tech & EV Conference.
December 06, 2021 06:45 ET | Worksport Ltd
Mississauga, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Worksport Ltd (Nasdaq-CM: WKSP) (the “Company”) announced today that it will be presenting virtually at the upcoming Sequire Clean Tech & EV...
Merus logo.jpg
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
December 06, 2021 06:42 ET | Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...
TM_Logo_Color_DarkFont.png
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma
December 06, 2021 06:30 ET | SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Dec. 06, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
ADAG Logo.jpg
Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021
December 06, 2021 06:30 ET | Adagene, Inc.
SAN DIEGO and SUZHOU, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference
December 06, 2021 06:05 ET | MannKind
WESTLAKE VILLAGE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
bolt_logo.png
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
December 06, 2021 06:00 ET | Bolt Biotherapeutics, Inc.
Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference...
AIH.png
Aesthetic Medical International Announces Business Updates on Newly-acquired Non-surgical Business in Guangzhou
December 06, 2021 05:30 ET | Aesthetic Medical International Holdings Group Limited
SHENZHEN, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in...
Wood Mackenzie Appoints Elena Belletti as Head of Carbon Research
December 06, 2021 04:00 ET | Verisk Analytics, Inc.
LONDON/HOUSTON/SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Wood Mackenzie, a Verisk business (Nasdaq:VRSK), has appointed Elena Belletti as Head of Carbon Research within the company’s Energy...
MolecularPartners_Logo.jpg
Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021
December 06, 2021 01:00 ET | Molecular Partners
First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions in viral load and complete COVID-19 clinical...